8-K: AN2 Therapeutics Reports Q4/FY25 Results, Extends Runway

AN2 Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting pipeline advancements and a private placement extending its cash runway into 2029.

Summary

• Net loss for the full year 2025 was $35.2 million, a decrease from $51.3 million in 2024.
• Net loss for the fourth quarter of 2025 increased to $8.7 million, compared to $7.5 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $60.0 million at December 31, 2025.
• A private placement in March 2026 raised approximately $40 million, extending the company's cash runway into 2029.
• A Phase 2 study of oral epetraborole in polycythemia vera (PV) is expected to begin in 3Q26, with potential data readouts starting in 4Q26 and continuing throughout 2027.
• Enrollment for a Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease is expected to begin in 1Q26, with topline results anticipated in late 2027.
• The Phase 1 first-in-human trial of oral AN2-502998 for Chagas disease is nearing completion, with initial clinical data expected in 1Q26; a Phase 2 proof-of-concept study is planned for 2026.
• The company is on track to advance two boron-based oncology compounds into development in 2026.
• AN2 Therapeutics announced a collaboration with GSK to develop new therapies for tuberculosis (TB), supported by a third year of funding from the Gates Foundation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, driven by significant pipeline progress across multiple therapeutic areas and a successful capital raise that substantially extends the company's financial runway. While Q4 net loss increased, the full-year financial improvements and strategic advancements outweigh this.

Positives

• Full year 2025 net loss decreased significantly to $35.2 million from $51.3 million in 2024.
• Full year 2025 Research and Development (R&D) expenses decreased to $24.8 million from $40.5 million in 2024.
• Full year 2025 General and Administrative (G&A) expenses decreased to $13.3 million from $14.1 million in 2024.
• The company successfully completed a private placement in March 2026, raising approximately $40 million.
• The private placement extends the company's projected cash runway into 2029 under the current operating plan.
• Expansion of oral epetraborole into a Phase 2 trial for polycythemia vera (PV) highlights growing pipeline opportunities.
• The U.S. FDA cleared an Investigational New Drug Application (IND) for a Phase 2 investigator-initiated study of epetraborole in M. abscessus lung disease.
• AN2-502998 for Chagas disease demonstrated curative activity in preclinical studies, including in nonhuman primates with naturally acquired chronic infections, which may be more predictive of human efficacy.
• Potential eligibility for a priority review voucher upon FDA approval of a Chagas disease treatment, incentivizing development for neglected infectious diseases.
• Plans to advance two boron-based oncology candidates into development in 2026, demonstrating platform versatility.
• Collaboration agreement with GSK and continued funding from the Gates Foundation for tuberculosis (TB) therapies.

Negatives

• Net loss for the fourth quarter of 2025 increased to $8.7 million, compared to $7.5 million for the same period in 2024.
• Research and Development (R&D) expenses for the fourth quarter of 2025 increased to $6.9 million, compared to $5.4 million for the same period in 2024.
• Interest income for the full year 2025 decreased to $2.9 million from $5.5 million in 2024.
• Interest income for the fourth quarter of 2025 decreased to $0.6 million from $1.1 million in 2024, attributed to lower cash, cash equivalents, and investment balances, and lower interest rates.
• Cash, cash equivalents, and investments decreased to $60.0 million at December 31, 2025, from $92.087 million at December 31, 2024.

Risks

• Ability to implement plans for the internal boron chemistry platform and pipeline programs.
• Timely enrollment of patients in AN2's clinical trials and investigator-initiated clinical trials.
• Disruptions at the FDA and other government agencies caused by funding shortages, staff reductions, and statutory, regulatory, and policy changes.
• Ability to procure sufficient supply of product candidates for clinical trials.
• Potential for results from clinical trials to differ from preclinical, early clinical, preliminary, or expected results.
• The ability of particular preclinical models in non-human primates to predict safety and efficacy in humans.
• Significant adverse events, toxicities, or other undesirable side effects associated with product candidates.
• The significant uncertainty associated with product candidates ever receiving any regulatory approvals.
• Continued government funding of the development program for melioidosis.
• Ability to obtain, maintain, or protect intellectual property rights related to current and future product candidates.
• Implementation of strategic plans for the business and product candidates.
• The sufficiency of capital resources and need for additional capital to achieve goals.
• Global macroeconomic conditions and global conflicts.

Future Outlook

The company expects to initiate three Phase 2 studies in 2026 for polycythemia vera, M. abscessus complex lung disease, and Chagas disease, with initial data readouts anticipated from late 2026 through 2027. Additionally, two boron-based oncology candidates are planned to advance into development in 2026. The recent private placement has extended the company's cash runway into 2029, supporting these planned advancements.

Management Comments

• "Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2s boron chemistry pipeline and our commitment to addressing serious, underserved diseases."
• "It also represents one of three proof-of-concept catalysts we believe we are well positioned to achieve in the next two years, including the Phase 2 investigator-initiated trial in M. abscessus complex lung disease and a Phase 2 proof-of-concept study in chronic Chagas disease planned for later this year, pending the outcome of our Phase 1 study."
• "Looking ahead, we remain on track to bring two boron-based oncology candidates into development in 2026, further demonstrating the versatility of our platform."
• "I'm proud of the momentum we're carrying into the year and the continued execution from our team as we work to deliver impactful therapies to patients with urgent unmet needs."

Industry Context

StockSavvy.ai notes that AN2 Therapeutics is leveraging its boron chemistry platform to address a diverse range of therapeutic areas, including hematologic diseases (PV), infectious diseases (M. abscessus, Chagas, TB, melioidosis), and oncology. This broad application strategy, coupled with collaborations like the one with GSK and funding from the Gates Foundation, positions the company to tackle significant unmet medical needs, particularly in neglected infectious diseases where a priority review voucher could provide a competitive advantage. The focus on novel small molecules in areas with limited or no FDA-approved treatments suggests a high-risk, high-reward strategy common in early-stage biopharma.

Comparison to Industry Standards

• The company's focus on neglected infectious diseases like Chagas disease and M. abscessus lung disease aligns with a growing industry trend to address global health challenges, often supported by non-profit organizations and government grants, similar to efforts by larger pharmaceutical companies and organizations like the Bill & Melinda Gates Foundation.
• The pursuit of a priority review voucher for Chagas disease is a common incentive mechanism used by the FDA to encourage development in underserved areas, a strategy also employed by companies developing treatments for rare pediatric diseases.
• The advancement of multiple candidates (three Phase 2 studies, two preclinical oncology candidates) from a single chemistry platform (boron chemistry) demonstrates a pipeline diversification strategy, comparable to other small to mid-cap biotechs aiming to de-risk their portfolios.
• The collaboration with GSK for TB therapies indicates a validation of AN2's platform by a major global biopharma, similar to partnerships seen across the industry where smaller innovative companies team up with larger players for development and commercialization.

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, pipeline advancements, and potential for future value creation from clinical milestones and potential priority review voucher.
• Patients: Potential for new treatment options for serious, underserved diseases like polycythemia vera, M. abscessus lung disease, and Chagas disease, which currently have limited or no FDA-approved therapies.
• Employees: Continued employment and potential growth opportunities as pipeline advances.
• Creditors: Improved financial stability due to extended cash runway.
• Partners (GSK, Gates Foundation, OHSU): Continued collaboration and progress on shared research and development goals.

Next Steps

• Initiate enrollment for Phase 2 M. abscessus complex lung disease study in 1Q26.
• Receive initial clinical data from Phase 1 Chagas disease trial in 1Q26.
• Initiate Phase 2 proof-of-concept study in chronic Chagas disease in 2026 (pending Phase 1 results).
• Advance two boron-based oncology candidates into development in 2026.
• Initiate Phase 2 trial for oral epetraborole in PV in India in 3Q26.
• Provide periodic data readouts for PV Phase 2 study beginning 4Q26 and throughout 2027.
• Report topline results for Phase 2 M. abscessus complex lung disease study in late 2027.

Key Dates

Recommendation

The company has demonstrated strong execution in advancing its diverse pipeline, with three Phase 2 studies expected to initiate in 2026 and two oncology candidates moving into development. The successful private placement significantly de-risks the company's financial position by extending its cash runway into 2029, providing ample time to reach critical clinical milestones. The potential for a priority review voucher for Chagas disease and collaborations with GSK and the Gates Foundation further enhance its long-term value proposition, making it an attractive investment for growth-oriented investors.

Keywords

AN2 Therapeutics, ANTX, biopharmaceutical, boron chemistry, polycythemia vera, M. abscessus lung disease, Chagas disease, oncology, tuberculosis, clinical trials, Phase 2, drug development, financial results, private placement, cash runway